twitter Linkedin acp Contact Us

Joint venture between Evonik and Shandong Vland Biotech commences in China

The joint venture aims to develop and expand gut health solutions products including probiotics for farm animals in China. (Image source: Vland Biotech)

Evonik Vland Biotech, a joint venture co-built by Evonik China Co Ltd and Shandong Vland Biotech Co Ltd. officially commenced operation on 14 March in Qingdao, China 

Headquartered in Vland Biotech Innovation Park in Qingdao, the joint venture aims to develop and expand gut health solutions products including probiotics for China's farm animals. Head of Evonik's life science division Nutrition & Care, the Animal Nutrition business line, Johann-Caspar Gammelin highlighted that their cooperation with Vland was a crucial step in realising their commitment to providing biosolutions including probiotics for animal gut health for the feed industry. 

The agreement will allow Evonik to distribute the joint venture’s portfolio outside of the Greater China region, while also allowing the company to expand its gut health solutions by adding broader formulation elements to its global product portfolio. 

"Vland and Evonik have been expanding and deepening our cooperation areas in the past decade," said chairman and president of Vland Group, Chen Gang. The joint venture will make full use of and give full play to each other’s strengths, and deliver efficient products and solutions in animal gut health for users both in China and abroad."

General manager of Evonik Vland Biotech (Shandong) Co Ltd., Dr Wang Xu agreed that the joint venture would greatly benefit from the strong innovation capabilities, applied technology expertise and excellent reputation of the two parent companies, thereby delivering innovative products and solutions to the market and creating more value for their customers. 

For more information, visit: https://corporate.evonik.cn/en and http://www.vlandbiochem.com/